Simone Bastrup Israelsen
Research Subjects
Simone Bastrup Israelsen has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Thomas Benfield
Department of Infectious Diseases, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
9 shared publications- Thomas Benfield
Department of Infectious Diseases Copenhagen University Hospital‐Amager and Hvidovre Hvidovre Denmark
8 shared publications Pernille Ravn
Department of Internal Medicine, Section of Infectious Diseases, Copenhagen University Hospital – Herlev and Gentofte, Gentofte, Denmark
4 shared publications- Sandra Tingsgård
Center of Research & Disruption of Infectious Diseases, Department of Infectious Diseases, Copenhagen University Hospital–Amager and Hvidovre, Hvidovre, Denmark
4 shared publications Lilian Kolte
Department of Respiratory Medicine and Infectious Diseases, Copenhagen University Hospital–Nordsjaelland , Hilleroed
3 shared publications- Markus Fally
Section for Respiratory Medicine, Department of Internal Medicine, Zealand University Hospital – Roskilde, Roskilde, Denmark
3 shared publications
Latest Publications
- Open Access
- 14 October 2025
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 21 (4) , 250190
The use of macrolides in the treatment of community-acquired pneumonia: risks and benefits
This Journal club aims to evaluate the recent evidence about the potential benefits of macrolides as add-on therapy in the treatment of community-acquired pneumonia (CAP), an area where the data remain conflicting. Four studies with diverse methodology (the ACCESS trial, a Greek cohort study, a UK-based cohort study and a recent meta-analysis) have aimed to assess either potential immunomodulatory effects, clinical response or hard end-points like mortality when macrolides are added to the treatment regimen for hospitalised patients with CAP. The ACCESS trial, a randomised controlled trial (RCT), demonstrated improved early clinical response and immunomodulatory effects with clarithromycin, while the Greek cohort study showed reduced 28-day mortality and delayed organ dysfunction with clarithromycin. The cohort study from the UK found no added benefit of macrolides on 30-day mortality or decline in Sequential Organ Failure Assessment score. The recent meta-analysis supported a survival advantage of macrolides, favouring clarithromycin over azithromycin. However, study limitations like heterogeneity, confounding risks and the lack of head-to-head comparisons of individual macrolides remain of concern. Macrolide treatment decisions may benefit from individualised risk assessment; however, future research should focus on identifying subgroups who might benefit from macrolides and comparative analyses of macrolide agents through large-scale RCTs.
- 14 October 2025
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 21 (4) , 250190
Open AccessThe use of macrolides in the treatment of community-acquired pneumonia: risks and benefits
This Journal club aims to evaluate the recent evidence about the potential benefits of macrolides as add-on therapy in the treatment of community-acquired pneumonia (CAP), an area where the data remain conflicting. Four studies with diverse methodology (the ACCESS trial, a Greek cohort study, a UK-based cohort study and a recent meta-analysis) have aimed to assess either potential immunomodulatory effects, clinical response or hard end-points like mortality when macrolides are added to the treatment regimen for hospitalised patients with CAP. The ACCESS trial, a randomised controlled trial (RCT), demonstrated improved early clinical response and immunomodulatory effects with clarithromycin, while the Greek cohort study showed reduced 28-day mortality and delayed organ dysfunction with clarithromycin. The cohort study from the UK found no added benefit of macrolides on 30-day mortality or decline in Sequential Organ Failure Assessment score. The recent meta-analysis supported a survival advantage of macrolides, favouring clarithromycin over azithromycin. However, study limitations like heterogeneity, confounding risks and the lack of head-to-head comparisons of individual macrolides remain of concern. Macrolide treatment decisions may benefit from individualised risk assessment; however, future research should focus on identifying subgroups who might benefit from macrolides and comparative analyses of macrolide agents through large-scale RCTs.
- 11 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , 1152-1158
The Impact of Lower Respiratory Tract Sample Cultures on Outcomes in Community-Acquired Pneumonia: A Propensity Score–Matched Cohort Study
Background: This study aimed to determine whether collecting a lower respiratory tract sample (LRTS) for bacterial microscopy, culture, and resistance (MCR) testing affects outcomes in patients with community-acquired pneumonia (CAP). Methods: This was a cohort study including adults admitted to hospital with CAP. The primary outcome was the duration of narrow-spectrum antibiotic treatment. Secondary outcomes included intravenous and total antibiotic durations, time to discharge, and 90-day mortality. Propensity score matching (PSM) balanced covariates between those who did and did not have an LRTS taken. Subgroup analyses focused on CAP due to Streptococcus pneumoniae or Haemophilus influenzae. Results: After PSM, the cohort consisted of 1434 patients. LRTS collection did not impact narrow-spectrum antibiotic use but was associated with longer intravenous (0.6 days longer, P = .001) and total antibiotic treatments (10.4 vs 9.9 days, P = .036). Time-to-event analysis showed lower probability of early discharge for those with an LRTS (hazard ratio [HR], 0.88 [95% confidence interval {CI}:, .79–.98]) and higher probability for those with CAP due to S. pneumoniae or H. influenzae (HR, 1.44 [95% CI: 1.22–1.71]). Survival analysis showed lower 90-day mortality for patients with an LRTS (HR, 0.78 [95% CI: .61–.99]) and for those with CAP due to S. pneumoniae or H. influenzae (HR, 0.38 [95% CI: .24–.62]). Conclusions: LRTS collection did not directly affect the use of narrow-spectrum antibiotics but was associated with extended antibiotic treatments overall. Additionally, LRTS collection was linked to longer hospital stays and reduced mortality. Until more sensitive methods for determining CAP etiology become available, LRTS MCR testing should remain a standard investigation for patients admitted with CAP.
- 11 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , 1152-1158
The Impact of Lower Respiratory Tract Sample Cultures on Outcomes in Community-Acquired Pneumonia: A Propensity Score–Matched Cohort Study
Background: This study aimed to determine whether collecting a lower respiratory tract sample (LRTS) for bacterial microscopy, culture, and resistance (MCR) testing affects outcomes in patients with community-acquired pneumonia (CAP). Methods: This was a cohort study including adults admitted to hospital with CAP. The primary outcome was the duration of narrow-spectrum antibiotic treatment. Secondary outcomes included intravenous and total antibiotic durations, time to discharge, and 90-day mortality. Propensity score matching (PSM) balanced covariates between those who did and did not have an LRTS taken. Subgroup analyses focused on CAP due to Streptococcus pneumoniae or Haemophilus influenzae. Results: After PSM, the cohort consisted of 1434 patients. LRTS collection did not impact narrow-spectrum antibiotic use but was associated with longer intravenous (0.6 days longer, P = .001) and total antibiotic treatments (10.4 vs 9.9 days, P = .036). Time-to-event analysis showed lower probability of early discharge for those with an LRTS (hazard ratio [HR], 0.88 [95% confidence interval {CI}:, .79–.98]) and higher probability for those with CAP due to S. pneumoniae or H. influenzae (HR, 1.44 [95% CI: 1.22–1.71]). Survival analysis showed lower 90-day mortality for patients with an LRTS (HR, 0.78 [95% CI: .61–.99]) and for those with CAP due to S. pneumoniae or H. influenzae (HR, 0.38 [95% CI: .24–.62]). Conclusions: LRTS collection did not directly affect the use of narrow-spectrum antibiotics but was associated with extended antibiotic treatments overall. Additionally, LRTS collection was linked to longer hospital stays and reduced mortality. Until more sensitive methods for determining CAP etiology become available, LRTS MCR testing should remain a standard investigation for patients admitted with CAP.
- Open Access
- 22 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (5) , 2400054
Reassessing Halm's clinical stability criteria in community-acquired pneumonia management
Background: Halm's clinical stability criteria have long guided antibiotic treatment and hospital discharge decisions for patients hospitalised with community-acquired pneumonia (CAP). Originally introduced in 1998, these criteria were established based on a relatively small and select patient population. Consequently, our study aims to reassess their applicability in the management of CAP in a contemporary real-world setting.Methods: This cohort study included 2918 immunocompetent patients hospitalised with CAP from three hospitals in Denmark between 2017 and 2020. The primary outcome was time to achieve clinical stability as defined by Halm's criteria. Additionally, we examined recurrence of clinical instability and severe complications. Cumulative incidence function or Kaplan–Meier survival curves were used to analyse these outcomes, considering competing risks.Results: The study population primarily comprised elderly individuals (median age 75 years) with significant comorbidities. The median time to clinical stability according to Halm's criteria was 4 days, with one-fifth experiencing recurrence of instability after early clinical response (stability within 3 days). Severe complications within 30 days mainly comprised mortality, with rates of 5.1% (64/1257) overall in those with early clinical response, 1.7% (18/1045) in the subgroup without do-not-resuscitate orders and 17.3% (276/1595) among the rest.Conclusion: Halm's clinical stability criteria effectively classify CAP patients with different disease courses, yet achieving stability required more time in this ageing population with substantial comorbidities and more severe disease. Early clinical response indicates reduced risk of complications, especially in those without do-not-resuscitate orders.
- 22 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (5) , 2400054
Open AccessReassessing Halm's clinical stability criteria in community-acquired pneumonia management
Background: Halm's clinical stability criteria have long guided antibiotic treatment and hospital discharge decisions for patients hospitalised with community-acquired pneumonia (CAP). Originally introduced in 1998, these criteria were established based on a relatively small and select patient population. Consequently, our study aims to reassess their applicability in the management of CAP in a contemporary real-world setting.Methods: This cohort study included 2918 immunocompetent patients hospitalised with CAP from three hospitals in Denmark between 2017 and 2020. The primary outcome was time to achieve clinical stability as defined by Halm's criteria. Additionally, we examined recurrence of clinical instability and severe complications. Cumulative incidence function or Kaplan–Meier survival curves were used to analyse these outcomes, considering competing risks.Results: The study population primarily comprised elderly individuals (median age 75 years) with significant comorbidities. The median time to clinical stability according to Halm's criteria was 4 days, with one-fifth experiencing recurrence of instability after early clinical response (stability within 3 days). Severe complications within 30 days mainly comprised mortality, with rates of 5.1% (64/1257) overall in those with early clinical response, 1.7% (18/1045) in the subgroup without do-not-resuscitate orders and 17.3% (276/1595) among the rest.Conclusion: Halm's clinical stability criteria effectively classify CAP patients with different disease courses, yet achieving stability required more time in this ageing population with substantial comorbidities and more severe disease. Early clinical response indicates reduced risk of complications, especially in those without do-not-resuscitate orders.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
241. Early switch from intravenous to oral antibiotics in patients with Gram-negative bacteremia – a target trial emulation
Gram-negative bacteremia is a global health concern, that continues to cause significant morbidity and mortality. Intravenous (IV) antibiotics are typically the first-line treatment; however, it is unclear when it is appropriate to switch to oral antibiotics in order to maintain positive outcomes. An early switch from intravenous to oral antibiotics may have several advantages, including reduced hospital stay, lower healthcare costs, and improved patient quality of life. This study investigates the effectiveness of early switch to oral antibiotics in patients with Gram-negative bacteremia using a target trial framework. We outlined the protocol for a target trial to estimate the effect of 1) switching to oral antibiotics within four days after initial blood culture compared with 2) continuing IV antibiotic treatment throughout the treatment course on 90-day all-cause mortality. We then emulated the trial using a cohort of adult patients with Gram-negative bacteremia from 2018 through 2022 admitted to four hospitals in the Capital Region of Denmark. Patients who were immunosuppressed, transitioned to hospice care, had polymicrobial infection, were not clinically stable within four days of blood culture, or did not receive adequate empirical antibiotic treatment were excluded. Inverse probability of treatment weighting was applied to adjust for confounding. Intention-to-treat analysis was performed using pooled logistic regression to estimate absolute risk, risk difference, and risk ratio. 95% confidence intervals (CI) were computed using bootstrapping. Our findings indicate that an early switch to oral antibiotic treatment within four days may be a safe and effective alternative to continued IV treatment in patients hospitalised with uncomplicated Gram-negative bacteremia. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access241. Early switch from intravenous to oral antibiotics in patients with Gram-negative bacteremia – a target trial emulation
Gram-negative bacteremia is a global health concern, that continues to cause significant morbidity and mortality. Intravenous (IV) antibiotics are typically the first-line treatment; however, it is unclear when it is appropriate to switch to oral antibiotics in order to maintain positive outcomes. An early switch from intravenous to oral antibiotics may have several advantages, including reduced hospital stay, lower healthcare costs, and improved patient quality of life. This study investigates the effectiveness of early switch to oral antibiotics in patients with Gram-negative bacteremia using a target trial framework. We outlined the protocol for a target trial to estimate the effect of 1) switching to oral antibiotics within four days after initial blood culture compared with 2) continuing IV antibiotic treatment throughout the treatment course on 90-day all-cause mortality. We then emulated the trial using a cohort of adult patients with Gram-negative bacteremia from 2018 through 2022 admitted to four hospitals in the Capital Region of Denmark. Patients who were immunosuppressed, transitioned to hospice care, had polymicrobial infection, were not clinically stable within four days of blood culture, or did not receive adequate empirical antibiotic treatment were excluded. Inverse probability of treatment weighting was applied to adjust for confounding. Intention-to-treat analysis was performed using pooled logistic regression to estimate absolute risk, risk difference, and risk ratio. 95% confidence intervals (CI) were computed using bootstrapping. Our findings indicate that an early switch to oral antibiotic treatment within four days may be a safe and effective alternative to continued IV treatment in patients hospitalised with uncomplicated Gram-negative bacteremia. All Authors: No reported disclosures
- 9 November 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 292-300
Emulating a Target Trial of Shorter Compared to Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia
Despite the availability of antimicrobial therapies, Gram-negative bacteremia remains a significant cause of morbidity and mortality on a global level. Recent randomized controlled trials support shorter antibiotic treatment duration for individuals with uncomplicated Gram-negative bacteremia. The target trial framework using the cloning approach utilizes real-world data but eliminates the issue of immortal time bias seen in observational studies by emulating the analysis of randomized trials with full adherence. A hypothetical target trial allocating individuals with Gram-negative bacteremia to either short antibiotic treatment duration (5-7 days) or longer antibiotic treatment duration (8-14 days) was specified and emulated using the cloning, censoring, and weighting approach. The primary outcome was 90-day all-cause mortality. Secondary outcome was a composite endpoint of clinical and microbiological relapse. The emulated trial included individuals from four hospitals in Copenhagen from 2018 through 2021. 1040 individuals were included. The median age of the cohort was 76 years, the majority were male (54%), had community-acquired Gram-negative bacteremia (86%), urinary tract infection as the source of the infection (78%), and Escherichia coli as the pathogen of the infection (73%). The adjusted 90-day risk difference in all-cause mortality was 1.3 (95% CI -0.7, 3.3), and the risk ratio was 1.12 (95% CI 0.89, 1.37). The adjusted 90-day risk difference in relapse was 0.7 (95% CI -2.3, 3.8), and the risk ratio was 1.07 (95% CI 0.71, 1.45). We found comparative outcomes for shorter treatment duration compared to longer treatment duration in patients with Gram-negative bacteremia.
- 9 November 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 292-300
Emulating a Target Trial of Shorter Compared to Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia
Despite the availability of antimicrobial therapies, Gram-negative bacteremia remains a significant cause of morbidity and mortality on a global level. Recent randomized controlled trials support shorter antibiotic treatment duration for individuals with uncomplicated Gram-negative bacteremia. The target trial framework using the cloning approach utilizes real-world data but eliminates the issue of immortal time bias seen in observational studies by emulating the analysis of randomized trials with full adherence. A hypothetical target trial allocating individuals with Gram-negative bacteremia to either short antibiotic treatment duration (5-7 days) or longer antibiotic treatment duration (8-14 days) was specified and emulated using the cloning, censoring, and weighting approach. The primary outcome was 90-day all-cause mortality. Secondary outcome was a composite endpoint of clinical and microbiological relapse. The emulated trial included individuals from four hospitals in Copenhagen from 2018 through 2021. 1040 individuals were included. The median age of the cohort was 76 years, the majority were male (54%), had community-acquired Gram-negative bacteremia (86%), urinary tract infection as the source of the infection (78%), and Escherichia coli as the pathogen of the infection (73%). The adjusted 90-day risk difference in all-cause mortality was 1.3 (95% CI -0.7, 3.3), and the risk ratio was 1.12 (95% CI 0.89, 1.37). The adjusted 90-day risk difference in relapse was 0.7 (95% CI -2.3, 3.8), and the risk ratio was 1.07 (95% CI 0.71, 1.45). We found comparative outcomes for shorter treatment duration compared to longer treatment duration in patients with Gram-negative bacteremia.
- Open Access
Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial
Introduction The optimal duration of antibiotic therapy for community-acquired pneumonia (CAP) is unsettled. Short-course therapy has proved successful in clinical trials but is not yet implemented in everyday clinical practice. Validation of results from randomised controlled trials is crucial to evaluate existing evidence and provide clinicians with assurance of using new treatment strategies. In a pragmatic framework, we aim to assess the use of short-course antibiotic therapy guided by the onset of clinical stability in patients hospitalised with CAP. Methods and analysis This study is a randomised controlled trial with a non-inferiority design that will examine the efficacy of short-course antibiotic therapy in patients hospitalised with CAP. From six hospitals across Denmark, we plan to enrol 564 patients between 2019 and 2024. Within 3–5 days after initiating antibiotic therapy, participants will be randomised 1:1 to parallel treatment arms: (1) short-course antibiotic therapy of 5 days or (2) antibiotic therapy of at least 7 days. The primary outcome will be 90-day readmission-free survival and will be estimated as an absolute risk difference with a predefined non-inferiority margin of −6%. Secondary outcomes will comprise other safety measures including new antibiotics, adverse events, length of hospital stay and postdischarge outpatient visits. Both intention-to-treat and per-protocol analyses will be performed. Ethics and dissemination This study has been approved by the Health Research Ethics Committee of the Capital Region of Denmark (identifier number: H-19014479). Trial data will be made available in anonymous form when the trial has ended. Trial registration number NCT04089787, ClinicalTrials.Gov.
Open AccessShort-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial
Introduction The optimal duration of antibiotic therapy for community-acquired pneumonia (CAP) is unsettled. Short-course therapy has proved successful in clinical trials but is not yet implemented in everyday clinical practice. Validation of results from randomised controlled trials is crucial to evaluate existing evidence and provide clinicians with assurance of using new treatment strategies. In a pragmatic framework, we aim to assess the use of short-course antibiotic therapy guided by the onset of clinical stability in patients hospitalised with CAP. Methods and analysis This study is a randomised controlled trial with a non-inferiority design that will examine the efficacy of short-course antibiotic therapy in patients hospitalised with CAP. From six hospitals across Denmark, we plan to enrol 564 patients between 2019 and 2024. Within 3–5 days after initiating antibiotic therapy, participants will be randomised 1:1 to parallel treatment arms: (1) short-course antibiotic therapy of 5 days or (2) antibiotic therapy of at least 7 days. The primary outcome will be 90-day readmission-free survival and will be estimated as an absolute risk difference with a predefined non-inferiority margin of −6%. Secondary outcomes will comprise other safety measures including new antibiotics, adverse events, length of hospital stay and postdischarge outpatient visits. Both intention-to-treat and per-protocol analyses will be performed. Ethics and dissemination This study has been approved by the Health Research Ethics Committee of the Capital Region of Denmark (identifier number: H-19014479). Trial data will be made available in anonymous form when the trial has ended. Trial registration number NCT04089787, ClinicalTrials.Gov.
- Open Access
Short course antibiotic treatment of Gram-negative bacteraemia (GNB5): a study protocol for a randomised controlled trial
Introduction: Prolonged use of antibiotics is closely related to antibiotic-associated infections, antimicrobial resistance and adverse drug events. The optimal duration of antibiotic treatment for Gram-negative bacteremia (GNB) with a urinary tract source of infection is poorly defined. Methods and analysis: Investigator-initiated multicentre, non-blinded, non-inferiority randomised controlled trial with two parallel treatment arms. One arm will receive shortened antibiotic treatment of 5 days and the other arm will receive antibiotic treatment of 7 days or longer. Randomisation will occur in equal proportion (1:1) no later than day 5 of effective antibiotic treatment as determined by antibiogram. Immunosuppressed patients and those with GNB due to non-fermenting bacilli ( Acinetobacter spp, Pseudomonas spp), Brucella spp, Fusobacterium spp or polymicrobial growth are ineligible. The primary endpoint is 90-day survival without clinical or microbiological failure to treatment. Secondary endpoints include all-cause mortality, total duration of antibiotic treatment, hospital readmission and Clostridioides difficile infection. Interim safety analysis will be performed after the recruitment of every 100 patients. Given an event rate of 12%, a non-inferiority margin of 10%, and 90% power, the required sample size to determine non-inferiority is 380 patients. Analyses will be performed on both intention-to-treat and per-protocol populations. Ethics and dissemination: The study is approved by the Danish Regional Committee on Health Research (H-19085920) and the Danish Medicines Agency (2019-003282-17). The results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. Trial registration number: ClinicalTrials.Gov:NCT04291768 .
Open AccessShort course antibiotic treatment of Gram-negative bacteraemia (GNB5): a study protocol for a randomised controlled trial
Introduction: Prolonged use of antibiotics is closely related to antibiotic-associated infections, antimicrobial resistance and adverse drug events. The optimal duration of antibiotic treatment for Gram-negative bacteremia (GNB) with a urinary tract source of infection is poorly defined. Methods and analysis: Investigator-initiated multicentre, non-blinded, non-inferiority randomised controlled trial with two parallel treatment arms. One arm will receive shortened antibiotic treatment of 5 days and the other arm will receive antibiotic treatment of 7 days or longer. Randomisation will occur in equal proportion (1:1) no later than day 5 of effective antibiotic treatment as determined by antibiogram. Immunosuppressed patients and those with GNB due to non-fermenting bacilli ( Acinetobacter spp, Pseudomonas spp), Brucella spp, Fusobacterium spp or polymicrobial growth are ineligible. The primary endpoint is 90-day survival without clinical or microbiological failure to treatment. Secondary endpoints include all-cause mortality, total duration of antibiotic treatment, hospital readmission and Clostridioides difficile infection. Interim safety analysis will be performed after the recruitment of every 100 patients. Given an event rate of 12%, a non-inferiority margin of 10%, and 90% power, the required sample size to determine non-inferiority is 380 patients. Analyses will be performed on both intention-to-treat and per-protocol populations. Ethics and dissemination: The study is approved by the Danish Regional Committee on Health Research (H-19085920) and the Danish Medicines Agency (2019-003282-17). The results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. Trial registration number: ClinicalTrials.Gov:NCT04291768 .
- Open Access
- 19 August 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (1) , 54-60
Short-course antibiotic therapy for hospitalized patients with early clinical response in community-acquired pneumonia: a multicentre cohort study
- 19 August 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (1) , 54-60
Open AccessShort-course antibiotic therapy for hospitalized patients with early clinical response in community-acquired pneumonia: a multicentre cohort study
- Open Access
- 21 January 2022
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 14 (5) , 493-501
Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3
The course of COVID-19 is unpredictable, ranging from asymptomatic to respiratory failure and death. Prognostic biomarkers are urgently needed. We hypothesized that long pentraxin PTX3 could be a valuable plasma biomarker due to its essential role in inflammatory processes. In a prospective hospitalized COVID-19 derivation cohort (n = 126) during the spring of 2020, we measured PTX3 within 4 days of admission. The predictive value of mechanical ventilation (MV) and 30-day mortality compared with clinical parameters and other markers of inflammation were assessed by logistic regression analysis and expressed as odds ratio (OR) with 95% confidence interval (CI). Analyses were repeated in a prospective validation cohort (n = 112) of hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. Thirty-day mortality in the derivation cohort was 26.2%. In patients who died, the median PTX3 concentration upon admission was 19.5 ng/mL (IQR: 12.5–33.3) versus 6.6 ng/mL (IQR 2.9–12.3) (p < 0.0001) for survivors. After adjustment for covariates, the odds of 30-day mortality increased two-fold for each doubling of PTX3 (OR 2.03 [95% CI: 1.23–3.34], p = 0.006), which was also observed in the validation cohort (OR 1.70 [95% CI: 1.09–2.67], p = 0.02). Similarly, PTX3 levels were associated with MV. After adjustment for covariates, OR of MV was 2.34 (95% CI: 1.33–4.12, p = 0.003) in the derivation cohort and 1.64 (95% CI: 1.03–2.62, p = 0.04) in the validation cohort. PTX3 appears to be a useful clinical biomarker to predict 30-day respiratory failure and mortality risk in COVID-19 patients treated with and without remdesivir and dexamethasone.
- 21 January 2022
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 14 (5) , 493-501
Open AccessPrediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3
The course of COVID-19 is unpredictable, ranging from asymptomatic to respiratory failure and death. Prognostic biomarkers are urgently needed. We hypothesized that long pentraxin PTX3 could be a valuable plasma biomarker due to its essential role in inflammatory processes. In a prospective hospitalized COVID-19 derivation cohort (n = 126) during the spring of 2020, we measured PTX3 within 4 days of admission. The predictive value of mechanical ventilation (MV) and 30-day mortality compared with clinical parameters and other markers of inflammation were assessed by logistic regression analysis and expressed as odds ratio (OR) with 95% confidence interval (CI). Analyses were repeated in a prospective validation cohort (n = 112) of hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. Thirty-day mortality in the derivation cohort was 26.2%. In patients who died, the median PTX3 concentration upon admission was 19.5 ng/mL (IQR: 12.5–33.3) versus 6.6 ng/mL (IQR 2.9–12.3) (p < 0.0001) for survivors. After adjustment for covariates, the odds of 30-day mortality increased two-fold for each doubling of PTX3 (OR 2.03 [95% CI: 1.23–3.34], p = 0.006), which was also observed in the validation cohort (OR 1.70 [95% CI: 1.09–2.67], p = 0.02). Similarly, PTX3 levels were associated with MV. After adjustment for covariates, OR of MV was 2.34 (95% CI: 1.33–4.12, p = 0.003) in the derivation cohort and 1.64 (95% CI: 1.03–2.62, p = 0.04) in the validation cohort. PTX3 appears to be a useful clinical biomarker to predict 30-day respiratory failure and mortality risk in COVID-19 patients treated with and without remdesivir and dexamethasone.
- 16 September 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (1) , 248-249
Reply
- 16 September 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (1) , 248-249
Reply